SUMMARY
Introduction Few studies have examined the incidence of virologic-confirmed influenza virus and respiratory syncytial virus (RSV) infections in community-dwelling older adults.
Methods We enrolled adults aged 60–89 years in Jiangsu Province, China and followed them weekly from December 2015–September 2017 to identify acute respiratory illnesses (ARI), collect illness information and respiratory specimens for laboratory testing.
Results 1,527 adults were enrolled, 0·4% reported ever receiving influenza vaccination. 95 PCR-confirmed influenza ARIs and 22 RSV ARIs were identified, among whom 4–5% required hospitalization. One death associated with RSV ARI while none for influenza ARIs was observed. From December 2015-August 2016, the cumulative incidences of influenza and RSV ARIs were 0·8% (95% CI:0·3–1·4) and 0·5% (95% CI:0·1–1·0), respectively. From September 2016-August 2017, the cumulative incidences were 6·1% (95% CI:4·7–7·7) and 1·0% (95% CI:0·5–1·6); the influenza and RSV ARI-associated hospitalization incidences were 0·3% (95% CI:0–0·8) and 0·1% (95% CI:0–0·2). Feverishness was more common in influenza (55%) than RSV ARIs (30%, p=0·03). Influenza (12·5 days, p=0·02) and RSV ARI symptoms (14·1 days, p=0·15) lasted longer compared to PCR-negative/other ARIs (11·0 days). Antibiotic use was more common for influenza (65%, p=0·02) and RSV (70%, p=0·04) ARIs than other ARIs (51%).
Conclusions We observed a higher incidence of influenza relative to RSV infections among community-dwelling older adults compared to prior studies. Our findings suggest older adults may benefit from receiving influenza and RSV vaccines to reduce the occurrence of illnesses.
Competing Interest Statement
BJC has consulted for AstraZeneca, Fosun Pharma, GSK, Haleon, Moderna, Novavax, Pfizer, Roche, and Sanofi Pasteur. The authors report no other potential conflicts of interest.
Funding Statement
This study was financially supported by the US Centers for Disease Control and Prevention through a contract (HHSD2002013M53890B: 200-2014-F-60406 to Abt Associates, Inc.), and a cooperative agreement (grant no. 1U01IP001064).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Board of the University of Hong Kong (UW15 404), the Institutional Review Board of Abt Associates (Abt IRB # 0837) upon which United States CDC relied, and the Ethics Committee of Jiangsu Provincial CDC (JSJK2015-B013-02).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
